Karyopharm Therapeutics Inc.
NASDAQ:KPTI
0.9032 (USD) • At close November 1, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 146.033 | 157.074 | 209.819 | 108.085 | 40.893 | 30.336 | 1.605 | 0.154 | 0.25 | 0.229 | 0.387 | 0.634 | 0.152 |
| Cost of Revenue
| 5.472 | 5.213 | 3.402 | 2.705 | 2.407 | 161.372 | 107.273 | 86.938 | 97.744 | 60.127 | 28.452 | 14.095 | 0 |
| Gross Profit
| 140.561 | 151.861 | 206.417 | 105.38 | 38.486 | -131.036 | -105.668 | -86.784 | -97.494 | -59.898 | -28.065 | -13.461 | 0.152 |
| Gross Profit Ratio
| 0.963 | 0.967 | 0.984 | 0.975 | 0.941 | -4.319 | -65.837 | -563.532 | -389.976 | -261.563 | -72.519 | -21.232 | 1 |
| Reseach & Development Expenses
| 138.22 | 148.662 | 160.842 | 150.813 | 122.34 | 161.372 | 107.273 | 86.938 | 97.744 | 60.127 | 28.452 | 14.095 | 8.623 |
| General & Administrative Expenses
| 131.881 | 145.401 | 143.846 | 126.417 | 0 | 48.847 | 24.87 | 23.948 | 21.582 | 15.948 | 5.885 | 2.429 | 1.84 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 131.881 | 145.401 | 143.846 | 126.417 | 105.421 | 48.847 | 24.87 | 23.948 | 21.582 | 15.948 | 5.885 | 2.429 | 1.84 |
| Other Expenses
| -0.356 | -0.083 | -0.085 | 0.206 | -0.05 | -0.033 | -0.081 | 0.01 | -0.002 | -0.027 | 0 | 0 | 0 |
| Operating Expenses
| 270.101 | 294.063 | 304.688 | 277.23 | 227.761 | 210.219 | 132.143 | 110.886 | 119.326 | 76.075 | 34.337 | 16.524 | 10.463 |
| Operating Income
| -129.54 | -142.202 | -98.271 | -171.85 | -189.275 | -179.883 | -130.538 | -110.732 | -119.076 | -75.846 | -33.95 | -15.89 | -10.311 |
| Operating Income Ratio
| -0.887 | -0.905 | -0.468 | -1.59 | -4.629 | -5.93 | -81.332 | -719.039 | -476.304 | -331.205 | -87.726 | -25.063 | -67.836 |
| Total Other Income Expenses Net
| -13.236 | -22.72 | -25.549 | -24.114 | -10.275 | 1.502 | -0.081 | 0.01 | -0.002 | -0.027 | 0.003 | 0.002 | 0 |
| Income Before Tax
| -142.776 | -164.922 | -123.82 | -195.964 | -199.55 | -178.381 | -128.921 | -109.438 | -118.181 | -75.777 | -33.947 | -15.888 | -10.311 |
| Income Before Tax Ratio
| -0.978 | -1.05 | -0.59 | -1.813 | -4.88 | -5.88 | -80.325 | -710.636 | -472.724 | -330.904 | -87.718 | -25.06 | -67.836 |
| Income Tax Expense
| 0.323 | 0.369 | 0.268 | 0.309 | 0.04 | 0.026 | 0.063 | 0.139 | -0.895 | -0.069 | -0.003 | -0.002 | 0 |
| Net Income
| -143.099 | -165.291 | -124.088 | -196.273 | -199.59 | -178.407 | -128.984 | -109.577 | -118.181 | -75.777 | -33.947 | -15.888 | -10.311 |
| Net Income Ratio
| -0.98 | -1.052 | -0.591 | -1.816 | -4.881 | -5.881 | -80.364 | -711.539 | -472.724 | -330.904 | -87.718 | -25.06 | -67.836 |
| EPS
| -1.25 | -2.02 | -1.65 | -2.72 | -3.22 | -3.14 | -2.81 | -2.92 | -3.32 | -2.43 | -5.59 | -6.64 | -10.27 |
| EPS Diluted
| -1.25 | -2.02 | -1.65 | -2.72 | -3.22 | -3.14 | -2.81 | -2.92 | -3.32 | -2.43 | -5.59 | -6.64 | -10.27 |
| EBITDA
| -129.01 | -139.926 | -97.774 | -168.824 | -183.903 | -175.888 | -130.538 | -110.732 | -119.076 | -75.776 | -33.95 | -15.766 | -10.228 |
| EBITDA Ratio
| -0.883 | -0.891 | -0.466 | -1.562 | -4.497 | -5.798 | -81.332 | -719.039 | -476.304 | -330.9 | -87.726 | -24.868 | -67.289 |